Literature DB >> 7901759

The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia.

A J Stoessl1, E Polanski, H Frydryszak.   

Abstract

The effects of both opiate agonists and the opiate antagonist naloxone were examined in a rodent model of tardive dyskinesia (TD). Chronic (approximately 20 weeks) administration of fluphenazine resulted in the emergence of vacuous chewing mouth movements (VCMs), a response which may be a useful model for this disorder. Fluphenazine-induced VCMs were not affected by a variety of selective opiate agonists administered intracerebroventricularly, but were potently suppressed by subcutaneous administration of the opiate antagonist naloxone. These findings suggest that increased opiate transmission may contribute to the pathogenesis of TD. Further investigation of the role of opiate antagonists in treating this disorder are warranted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901759     DOI: 10.1002/mds.870080405

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  B Henry; J M Brotchie
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

2.  Endomorphin-1: induction of motor behavior and lack of receptor desensitization.

Authors:  A Mehta; G Bot; T Reisine; M F Chesselet
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 3.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.